ESourcing Capability Model

Vial Announces the Addition of Dr. Christopher Sweeney of SAiGENCI and the University of Adelaide to their Oncology CRO Scientific Advisory Board

Retrieved on: 
Tuesday, December 20, 2022
Internal medicine, EDC, Ophthalmology, Dermatology, SAN, Harvard Medical School, Royal Adelaide Hospital, Gundersen Health System, Faculty, University, Indiana University School of Medicine, Neurology, Hematology, Associate, Multimedia, Cardiology, Gastroenterology, SAB, Dana–Farber Cancer Institute, ESourcing Capability Model, MBBS, Clinical research, Fine chemical, Medicine, Vial, Oncology

Dr. Sweeney will work closely with the company's leadership team to shape the scientific strategy of Vial's Oncology CRO products and services.

Key Points: 
  • Dr. Sweeney will work closely with the company's leadership team to shape the scientific strategy of Vial's Oncology CRO products and services.
  • "We are beyond thrilled that an eminent scientist such as Dr. Sweeney has decided to join our CRO's Oncology SAB.
  • Dr. Sweeney is the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI), and a professor of medicine at the University of Adelaide.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Dr. Peter Goadsby of the NIHR Wellcome Trust at the King's College Clinical Research Facility, London, Joins Vial's Neurology CRO as a Scientific Advisor

Retrieved on: 
Thursday, December 15, 2022
Dermatology, Central nervous system, Cardiology, Migraine, The Brain Prize, Patient, Entrepreneurship, Headache, Ophthalmology, Research, Neurology, Gastroenterology, University of California, San Francisco Fetal Treatment Center, ESourcing Capability Model, Multimedia, University, SAN, EDC, CGRP, Pharmaceutical industry, Fine chemical, Vial

Dr. Goadsby is the Director of the NIHR Wellcome Trust at the King's College Clinical Research Facility, London, and a Professor of Neurology at the University of California, San Francisco.

Key Points: 
  • Dr. Goadsby is the Director of the NIHR Wellcome Trust at the King's College Clinical Research Facility, London, and a Professor of Neurology at the University of California, San Francisco.
  • Dr. Goadsby is a world-renowned headache medicine specialist whose clinical research focuses on understanding the pathophysiology of and guiding the treatment of migraine and cluster headaches.
  • About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials for less cost.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Vial Announces the Addition of Dr. Veeral Sheth of the University Retina and Macula Associates and the University of Illinois, Chicago, to their Ophthalmology CRO Scientific Advisory Board

Retrieved on: 
Wednesday, December 14, 2022
Shelf Life, Champaign County, Illinois, Dermatology, Cardiology, Administration, Entrepreneurship, Clinical, University of Illinois School of Information Sciences, Eye, Research, Macular degeneration, Retina, Gastroenterology, ESourcing Capability Model, Multimedia, Clinical trial, University, Neurology, Diabetic retinopathy, SAB, SAN, EDC, MBA, Fine chemical, Vial, MD, Ophthalmology

Dr. Sheth will work closely with the company's leadership team to shape the scientific strategy of the Vial Ophthalmology CRO's products and services.

Key Points: 
  • Dr. Sheth will work closely with the company's leadership team to shape the scientific strategy of the Vial Ophthalmology CRO's products and services.
  • Dr. Sheth is the Director of Clinical Research at the University Retina and Macula Associates and a Clinical Assistant Professor at the University of Illinois, Chicago.
  • About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials for less cost.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

E Source selected to design, build, and operate New York's Integrated Energy Data Resource platform

Retrieved on: 
Monday, December 12, 2022
Elohist, Azkals Development Team, Development, Public utility, ESourcing Capability Model, Data science, New York State Energy Research and Development Authority, UI, Policy, IEDR, NYSERDA, Documentation, Renewable energy

BOULDER, Colo., Dec. 12, 2022 /PRNewswire/ -- E Source, the data solutions leader for the utility industry, today announced that it has been awarded a milestone contract by the New York State Energy Research and Development Authority (NYSERDA) to develop the state's Integrated Energy Data Resource (IEDR) platform. The first-of-its-kind platform will act as a secure, centralized repository of energy-related data for all electric, gas, and steam utilities—as well as other non-utility entities—across the state.

Key Points: 
  • BOULDER, Colo., Dec. 12, 2022 /PRNewswire/ -- ESource , the data solutions leader for the utility industry, today announced that it has been awarded a milestone contract by the New York State Energy Research and Development Authority (NYSERDA) to develop the state's Integrated Energy Data Resource (IEDR) platform .
  • The first-of-its-kind platform will act as a secure, centralized repository of energy-related data for all electric, gas, and steam utilitiesas well as other non-utility entitiesacross the state.
  • To develop and implement the IEDR platform, ESource will lead a Development Team of utility innovation leaders including UtilityAPI, Flux Tailor, TRC Companies, and HumanLogic.
  • By integrating, analyzing, and making energy data accessible, the IEDR platform will benefit New York's key clean-energy stakeholders in many ways, across use cases , while facilitating communications among all.

RealTime Software Solutions Acquires Complion

Retrieved on: 
Wednesday, December 7, 2022
Factor X, Clinical data management, NIH, Acquisition, Clinical trial management system, Edoc, Partnership, Research, Hospital, CTMS, Cros, Academic health science centre, ESourcing Capability Model, Epiregulin, MD–PhD, AMCS, SAN, TEXT, Pharmaceutical industry, Online shopping, Text

SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).

Key Points: 
  • SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).
  • The partnership of RealTime and Complion bolsters the combined organization's position as a leading provider of eClinical solutions to make clinical research processes more efficient and compliant.
  • "This combination accelerates our mission to deliver leading eRegulatory and additional innovative solutions from RealTime to our customers."
  • About RealTime: RealTime Software Solutions, LLC provides innovative software solutions for clinical research sites, site networks, sponsors and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done.

Sitero and CRIO Announce Strategic Partnership

Retrieved on: 
Wednesday, December 7, 2022
Data management, IBC, Partnership, Clinical, Research, ESourcing Capability Model, Clinical trial, Safety, IRB, Ethics, Medical device, Medical imaging, Pharmaceutical industry, CRIO

MIAMI, Dec. 7, 2022 /PRNewswire/ --Sitero and CRIO have launched a strategic partnership to lift the administrative burden of clinical research for sites and sponsors while improving patient safety, experience and outcomes.

Key Points: 
  • MIAMI, Dec. 7, 2022 /PRNewswire/ --Sitero and CRIO have launched a strategic partnership to lift the administrative burden of clinical research for sites and sponsors while improving patient safety, experience and outcomes.
  • The partnership revolutionizes trial execution by removing the need for manual, redundant and error-prone activities across the clinical lifecycle.
  • "We're proud to collaborate with CRIO to elevate quality, speed and patient centricity in clinical trials with the support of our teams as experienced partners," said Sankesh Abbhi, CEO of Sitero.
  • Users can view and control these functions through an intuitive, integrated services and software platform developed jointly by Sitero and CRIO.

Vial Announces the Addition of Dr. Michael W. Lawlor of the Medical College of Wisconsin and the Diverge Translational Science Laboratory to their Central Nervous System Scientific Advisory Board

Retrieved on: 
Wednesday, December 7, 2022
Dermatology, MD, Cardiology, Anatomy, Cell biology, Neuropathology, Medical college, Entrepreneurship, Ophthalmology, Research, Biomedical engineering, MGH, Neurology, Medical College of Wisconsin, Gastroenterology, Massachusetts General Hospital, Physiology, Neuroscience, Pathology, Journal, ESourcing Capability Model, Multimedia, Hospital, Experimental Neurology, SAB, Doctor of Philosophy, SAN, EDC, Loyola University, CNS, Fine chemical, Vial

Dr. Lawlor will work closely with the company's leadership team to shape the scientific strategy of Vial's Neurology CRO products and services.

Key Points: 
  • Dr. Lawlor will work closely with the company's leadership team to shape the scientific strategy of Vial's Neurology CRO products and services.
  • "We are honored to have such a remarkable and accomplished neuropathologist join Vial's CNS SAB," said Simon Burns, CEO and Co-Founder of Vial.
  • Dr. Lawlor is a tenured professor of pathology, neurology, biomedical engineering, physiology, cell biology, neurobiology, and anatomy at the Medical College of Wisconsin and the founder, owner, and CEO of Diverge Translational Science Laboratory.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Vial: Faster, Better, Cheaper CRO Powered by Technology, Announces Series B led by General Catalyst

Retrieved on: 
Wednesday, November 30, 2022
Data collection, ESourcing Capability Model, SAN, Cardiology, Communication, Patient recruitment, General Catalyst, Silicon, Cros, Cdx, Multimedia, PDF, BoxGroup, EMR, European Technology Platform on Smart Systems Integration, Dermatology, Ophthalmology, Gastroenterology, Cras, Neurology, Entrepreneurship, Clinical trial, Fine chemical, Vial, Microsoft Excel

Together the teams collaborated on building a technology platform that drives efficiencies in every step of a clinical trial.

Key Points: 
  • Together the teams collaborated on building a technology platform that drives efficiencies in every step of a clinical trial.
  • Vial's Technology Platform is made up of three key platforms: Site Startup platform, eSource platform and Patient Recruiting platform.
  • Vial is the CRO sponsors can trust to be a true partner and deliver for their clinical trials.
  • Vial operates across multiple therapeutic areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board

Retrieved on: 
Monday, November 28, 2022
ESourcing Capability Model, SAN, Cardiology, Gibbs Cancer Center & Research Institute, University, Lean, Multimedia, United States Air Force Scientific Advisory Board, Hotel manager, Patient, EDC, MD, Dermatology, Medical director, Cancer, Ophthalmology, Digital technology, Gastroenterology, Cras, Neurology, Disease, Fine chemical, Online shopping, Vial, Oncology

SAN FRANCISCO, Nov. 27, 2022 /PRNewswire/ -- Vial , a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Marc Hoffmann, MD, to Vial's Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO, Nov. 27, 2022 /PRNewswire/ -- Vial , a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Marc Hoffmann, MD, to Vial's Scientific Advisory Board.
  • Dr. Hoffmann will work closely with the company's leadership team to shape the scientific strategy of Vial's Oncology CRO products and services.
  • Undoubtedly, Dr. Hoffmann will be an invaluable resource as we advance our Oncology CRO and technology platform," said Richard McCormick Jr., VP of Oncology at Vial.
  • Vial operates across multiple Therapeutic Areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Clinical ink Again Ranked Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 16, 2022
Growth, Arthur Seguin, Human, ESourcing Capability Model, Guest appearance, Cros, Patient, Deloitte Technology Fast 500, Biomarker, Science and technology in Asia, Telecommunication, Immunology, Neurology, Medical imaging, Pharmaceutical industry

Horsham, Pennsylvania, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Horsham, Pennsylvania; November 16, 2022 Clinical ink , a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.

Key Points: 
  • Horsham, Pennsylvania, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Horsham, Pennsylvania; November 16, 2022 Clinical ink , a global life science technology company, today announced its second consecutive listing on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.
  • Seguine said, At Clinical ink, we are committed to powering patient outcomes by converging data, technology, and patient science.
  • Our appearance on the respected Deloitte Technology Fast 500 list for two straight years is direct evidence of our growth and financial performance.
  • Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies both public and private in North America.